University Of California, San Francisco

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Mindfulness Based Approach to HIV Treatment Side Effects

Phase 1

Completed

Conditions: HIV Infections

Interventions: Behavioral: Mindfulness-based Stress Reduction (MBSR)

First Posted Date: 2006-04-11

Last Posted Date: 2016-05-16

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 76

Registration Number: NCT00312936

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Ketoconazole, Hydrocortisone, and GM-CSF in Treating Patients With Progressive Prostate Cancer After Hormone Therapy

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2006-04-03

Last Posted Date: 2019-08-05

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 49

Registration Number: NCT00309894

Locations: 🇺🇸
UCSF Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸
Veterans Affairs Medical Center - San Francisco, San Francisco, California, United States

Opioid and Cannabinoid Pharmacokinetic Interactions

Phase 1

Completed

Conditions: Pain

Interventions: Drug: Cannabis

First Posted Date: 2006-03-29

Last Posted Date: 2016-12-09

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 24

Registration Number: NCT00308555

Locations: 🇺🇸
Community Consortium, San Francisco, California, United States

GM-CSF Before Surgery in Treating Patients With Localized Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Biological: sargramostim
Other: immunohistochemistry staining method
Other: immunological diagnostic method
Other: laboratory biomarker analysis
Procedure: conventional surgery
Procedure: neoadjuvant therapy

First Posted Date: 2006-03-22

Last Posted Date: 2014-06-25

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 24

Registration Number: NCT00305669

Locations: 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

Bevacizumab and Letrozole in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer That Cannot Be Removed By Surgery

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Biological: bevacizumab
Drug: letrozole

First Posted Date: 2006-03-22

Last Posted Date: 2017-08-31

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 43

Registration Number: NCT00305825

Locations: 🇺🇸
UCSF Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remission

Phase 1

Completed

Conditions: Congenital Amegakaryocytic Thrombocytopenia
Diamond-blackfan Anemia
Fanconi Anemia
Leukemia
Severe Congenital Neutropenia
Thrombocytopenia

First Posted Date: 2006-03-22

Last Posted Date: 2012-11-12

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 40

Registration Number: NCT00305708

Locations: 🇺🇸
UCSF Comprehensive Cancer Center, San Francisco, California, United States

Evaluation of the Reliability, Validity, and Acceptability of the London Measure of Unplanned Pregnancy in a U.S. Population of Women

Completed

Conditions: Unplanned Pregnancy

First Posted Date: 2006-03-22

Last Posted Date: 2013-06-25

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 320

Registration Number: NCT00306007

Locations: 🇺🇸
San Francisco General Hospital, San Francisco, California, United States

The ICU Care Knowledge Study

Completed

Conditions: ICU Patient

First Posted Date: 2006-03-22

Last Posted Date: 2007-04-19

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 154

Registration Number: NCT00305981

Locations: 🇺🇸
San Francisco General Hospital ICU, San Francisco, California, United States

Efficacy Study of the Non-Pneumatic Anti-Shock Garment (NASG) in Egypt

Phase 1

Completed

Conditions: Hemorrhage
Hypovolemic Shock

Interventions: Device: Non-pneumatic Anti-shock Garment (NASG)

First Posted Date: 2006-03-21

Last Posted Date: 2013-05-14

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 990

Registration Number: NCT00305253

Locations: 🇪🇬
El-Galaa Teaching Hospital, Cairo, Egypt
🇪🇬
Assuit University Hospital, Assiut, Egypt

The Effects of Dietary Phosphate Intake on Calciotropic Hormones and FGF23.

Not Applicable

Withdrawn

Conditions: Healthy
Kidney Failure, Chronic

Interventions: Other: Dietary

First Posted Date: 2006-03-21

Last Posted Date: 2013-10-10

Lead Sponsor: University of California, San Francisco

Registration Number: NCT00305279

Locations: 🇺🇸
University of California, San Francisco, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy